

CFAO HEALTHCARE ACCELERATES ITS EXPANSION IN LUSOPHONE AFRICA WITH THE ACQUISITION OF MEDIMPORT, A PHARMACEUTICAL DISTRIBUTOR IN MOZAMBIQUE

Maputo, November 29, 2024 - CFAO Healthcare, a division of the CFAO Group, announces the acquisition of Medimport, one of Mozambique's leading pharmaceutical distributors, from the Portuguese laboratory BIAL. This operation marks a significant step in CFAO Healthcare's development strategy, consolidating its presence in the Portuguese-speaking countries of the African continent.

This acquisition is part of CFAO Healthcare's strategy to expand access to high-quality medicines in Africa. Present in 22 African countries, CFAO Healthcare specializes in the manufacture, distribution and supply of pharmaceutical and medical products, as well as related services. With its move into Mozambique, the division strengthens its presence in Portuguese-speaking Africa, where it already operates in Angola.

"CFAO Healthcare's entry into the Mozambican market confirms our strategy of geographic expansion across the Continent, and further consolidates our position as the pan-African leader in pharmaceutical distribution," said Jean-Marc Leccia, CEO of CFAO Healthcare.

"Our aim is to use our expertise to improve the health service provided to the people of Mozambique. By integrating Medimport, we aim to broaden access to high-quality pharmaceutical products, optimize the supply chain and foster the development of new strategic partnerships", says Ken Accajou, Deputy Managing Director & Head of CFAO Healthcare's Portuguese- and English-speaking Africa division.

Medimport will continue to build on its strong logistics network, serving nearly 1,200 pharmacies from its bases in Maputo and Nampula, while planning to expand its portfolio through this dynamic of expansion.

"Joining CFAO Healthcare is a major turning point for Medimport. It opens up promising development prospects for our teams, while strengthening our ability to meet the growing needs of the pharmaceutical market in Mozambique", said Jorge Ribeiro, Managing Director of Medimport.

For BIAL, this operation is in line with a logic of continuity and strengthened collaboration. "BIAL is fully dedicated to the discovery, development and marketing of medicines. The sale of Medimport to CFAO Healthcare is in line with BIAL's strategy of focusing on its core business and marks an important milestone for BIAL. It enables us to secure the continuity of our activities in Mozambique, while strengthening a solid strategic partnership with CFAO Healthcare, a key player in the pharmaceutical sector in Africa", explained Antonio Portela, BIAL's CEO.

About CFAO Group

With a revenue of €8.3 billion, access to 45 of the 54 countries in Africa and over 23,100 employees, the CFAO Group, Corporation For Africa & Overseas, contributes to growth and industrialization on the continent, and to the emergence of the middle class, by drawing on its local knowledge and expertise. As a partner to major global brands, the Group operates across the entire value chain - import, production, distribution - in line with the highest international standards. www.cfaogroup.com

With Africa For Africa

About CFAO Healthcare

Secure access to high-quality medicines in all African countries

As the leader in the pharmaceutical market in Africa, CFAO Healthcare supplies medicines and pharmaceutical products in more than 22 African countries and 6 FOTs thanks to highly structured distribution channels. We thus ensure our integrity from the storage site to the pharmacy. As a wholesale distributor and agent for world-renowned laboratories, we also manufacture medicines under license in Morocco and Algeria. A commitment that promotes employment by drawing on local know-how and the innovations of international pharmaceutical laboratories. cfaohealthcare.com

With Africa For Africa

MEDIA CONTACT

35°Nord – CFAO Media Relations Agency

For interview requests or to obtain further information

Romain GRANDJEAN rg@35nord.com +33651884300